Impact of Amyloid Imaging on Drug Development in Alzheimer's Disease

Overview

Journal Nucl Med Biol

Publisher Elsevier

Specialties Biology
Nuclear Medicine

Date 2007 Oct 9

PMID 17921032

Citations 29

Authors

Chester A Mathis

Brian J Lopresti

William E Klunk

Affiliations

Soon will be listed here.

Abstract

Imaging agents capable of assessing amyloid-beta (Abeta) content in vivo in the brains of Alzheimer's disease (AD) subjects likely will be important as diagnostic agents to detect Abeta plaques in the brain as well as to help test the amyloid cascade hypothesis of AD and as an aid to assess the efficacy of anti-amyloid therapeutics currently under development and in clinical trials. Positron emission tomography (PET) imaging studies of amyloid deposition in human subjects with several Abeta imaging agents are currently underway. We reported the first PET studies of the carbon 11-labeled thioflavin-T derivative Pittsburgh Compound B in 2004, and this work has subsequently been extended to include a variety of subject groups, including AD patients, mild cognitive impairment patients and healthy controls. The ability to quantify regional Abeta plaque load in the brains of living human subjects has provided a means to begin to apply this technology as a diagnostic agent to detect regional concentrations of Abeta plaques and as a surrogate marker of therapeutic efficacy in anti-amyloid drug trials.

Citing Articles

Ganoderma lucidum Triterpenoids (GLTs) Reduce Neuronal Apoptosis via Inhibition of ROCK Signal Pathway in APP/PS1 Transgenic Alzheimer's Disease Mice.

Yu N, Huang Y, Jiang Y, Zou L, Liu X, Liu S Oxid Med Cell Longev. 2020; 2020:9894037.

PMID: 32089787 PMC: 7008260. DOI: 10.1155/2020/9894037.

Physical Frailty and Amyloid-β Deposits in the Brains of Older Adults with Cognitive Frailty.

Yoon D, Lee J, Shin S, Kim Y, Song W J Clin Med. 2018; 7(7).

PMID: 29987248 PMC: 6068928. DOI: 10.3390/jcm7070169.

Computer-Aided Multi-Target Management of Emergent Alzheimer's Disease.

Kim H, Han H Bioinformation. 2018; 14(4):167-180.

PMID: 29983487 PMC: 6016757. DOI: 10.6026/97320630014167.

Fluid Biomarkers in Clinical Trials of Alzheimer's Disease Therapeutics.

Ritter A, Cummings J Front Neurol. 2015; 6:186.

PMID: 26379620 PMC: 4553391. DOI: 10.3389/fneur.2015.00186.

Novel PET/SPECT probes for imaging of tau in Alzheimer's disease.

Watanabe H, Ono M, Saji H ScientificWorldJournal. 2015; 2015:124192.

PMID: 25879047 PMC: 4386695. DOI: 10.1155/2015/124192.

References

Kuo Y, Emmerling M, Kasunic T, Kirkpatrick J, Murdoch G, Ball M . Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem. 1996; 271(8):4077-81. DOI: 10.1074/jbc.271.8.4077. View

Fraering P, Ye W, LaVoie M, Ostaszewski B, Selkoe D, Wolfe M . gamma-Secretase substrate selectivity can be modulated directly via interaction with a nucleotide-binding site. J Biol Chem. 2005; 280(51):41987-96. PMC: 1523323. DOI: 10.1074/jbc.M501368200. View

Forman M, Mufson E, Leurgans S, Pratico D, Joyce S, Leight S . Cortical biochemistry in MCI and Alzheimer disease: lack of correlation with clinical diagnosis. Neurology. 2007; 68(10):757-63. DOI: 10.1212/01.wnl.0000256373.39415.b1. View

Fox N, Black R, Gilman S, Rossor M, Griffith S, Jenkins L . Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology. 2005; 64(9):1563-72. DOI: 10.1212/01.WNL.0000159743.08996.99. View

Gilman S, Koller M, Black R, Jenkins L, Griffith S, Fox N . Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005; 64(9):1553-62. DOI: 10.1212/01.WNL.0000159740.16984.3C. View

Westerman M, Mariash A, Kotilinek L, Kawarabayashi T, Younkin L, Carlson G . The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci. 2002; 22(5):1858-67. PMC: 6758862. View

Oddo S, Caccamo A, Kitazawa M, Tseng B, LaFerla F . Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging. 2003; 24(8):1063-70. DOI: 10.1016/j.neurobiolaging.2003.08.012. View

Price J, Morris J . Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol. 1999; 45(3):358-68. DOI: 10.1002/1531-8249(199903)45:3<358::aid-ana12>3.0.co;2-x. View

Weggen S, ERIKSEN J, Das P, Sagi S, Wang R, Pietrzik C . A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature. 2001; 414(6860):212-6. DOI: 10.1038/35102591. View

10.

Mathis C, Klunk W, Price J, DeKosky S . Imaging technology for neurodegenerative diseases: progress toward detection of specific pathologies. Arch Neurol. 2005; 62(2):196-200. DOI: 10.1001/archneur.62.2.196. View

11.

Melnikova I . Therapies for Alzheimer's disease. Nat Rev Drug Discov. 2007; 6(5):341-2. DOI: 10.1038/nrd2314. View

12.

Gauthier S, Reisberg B, Zaudig M, Petersen R, Ritchie K, Broich K . Mild cognitive impairment. Lancet. 2006; 367(9518):1262-70. DOI: 10.1016/S0140-6736(06)68542-5. View

13.

Lemere C, Spooner E, LaFrancois J, Malester B, Mori C, Leverone J . Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice. Neurobiol Dis. 2003; 14(1):10-8. DOI: 10.1016/s0969-9961(03)00044-5. View

14.

Lambert M, Barlow A, Chromy B, Edwards C, Freed R, Liosatos M . Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A. 1998; 95(11):6448-53. PMC: 27787. DOI: 10.1073/pnas.95.11.6448. View

15.

Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T . Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999; 400(6740):173-7. DOI: 10.1038/22124. View

16.

Wolfe M . The gamma-secretase complex: membrane-embedded proteolytic ensemble. Biochemistry. 2006; 45(26):7931-9. DOI: 10.1021/bi060799c. View

17.

Billings L, Oddo S, Green K, McGaugh J, LaFerla F . Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron. 2005; 45(5):675-88. DOI: 10.1016/j.neuron.2005.01.040. View

18.

Mirra S, HEYMAN A, McKeel D, SUMI S, Crain B, Brownlee L . The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991; 41(4):479-86. DOI: 10.1212/wnl.41.4.479. View

19.

Klunk W, Wang Y, Huang G, Debnath M, Holt D, Shao L . The binding of 2-(4'-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci. 2003; 23(6):2086-92. PMC: 6741999. View

20.

Jorm A . Cross-national comparisons of the occurrence of Alzheimer's and vascular dementias. Eur Arch Psychiatry Clin Neurosci. 1991; 240(4-5):218-22. DOI: 10.1007/BF02189530. View